NK:IO is pioneering advancements in cancer treatment by focusing on the potential of Natural Killer (NK) cells, a vital component of the innate immune system. The company is developing innovative therapies that utilize NK cells and small molecules to target both hematological and solid tumors. Their approach addresses significant challenges in NK cell therapy, such as the difficulty in expanding NK cells to therapeutic levels and their tendency to become exhausted quickly. By leveraging discoveries made at Imperial College London, NK:IO has established proprietary technology platforms that enhance NK cell development and functionality, particularly using NK cells derived from umbilical cord blood stem cells.

The company's technology portfolio includes the development of first-generation wNK:IO cells, which are designed for cancer immunotherapy and exhibit improved expansion and functionality compared to existing NK cell technologies. Additionally, NK:IO is advancing engineered eNK:IO cells that have been modified to enhance their cytotoxic capabilities against tumors. Their dNK:IO platform focuses on small molecules that can mobilize and increase NK cell production in vivo, representing a novel strategy to bolster the immune response against tumors and chronic infections. These innovative technologies position NK:IO at the forefront of cancer immunotherapy, with ongoing research aimed at translating these advancements into effective clinical treatments.

United Kingdom

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours.

Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

NK:IO

Company Details